Adage Capital Partners Gp, L.L.C. Janux Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,525,000 shares of JANX stock, worth $58.9 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
2,525,000
Previous 3,654,574
30.91%
Holding current value
$58.9 Million
Previous $98.7 Million
40.89%
% of portfolio
0.1%
Previous 0.19%
Shares
12 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
55.9MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$261 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$104 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$68.1 Million3.15% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$54.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$51 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $971M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...